Abstract
Incidence
Worldwide, the incidence of neural tube defects (NTDs) varies from 0.17 to 6.39 per 1,000 live births. The declining prevalence of myelomeningocele, the most common NTD, is secondary to several factors including folic acid fortification, prenatal diagnosis with termination of affected fetuses, and unknown factors.
Impact of changes
Of those born with myelomeningocele, survival during infancy and preschool years has improved over the last 25 years (Bowman et al., Pediatr Neurosurg 34:114–120, 4). Fewer newborns today require shunt placement, which will hopefully improve the long-term mortality associated with this disease (Chakraborty et al., J Neurosurg Pediatr 1(5):361–365, 13, unpublished data). Of a cohort born in 1975–1979 and treated at a single US institution, 74% have survived into young adulthood.
Clinical implications
One of the greatest challenges facing these young adults is the transitioning of their medical care into an adult medical community.
Similar content being viewed by others
References
Adzick NS, Sutton LN, Crombleholme TM, Flake AW (1998) Successful fetal surgery for spina bifida. Lancet 352:1675–1676
Blumenfeld Z, Siegler E, Bronstein M (1993) The early diagnosis of neural tube defects. Prenat Diagn 13:863–871
Botto LD, Lisi A, Robert-Gnansia E, Erickson JD, Vollset SE, Mastroiacovo P, Botting B, Cocchi G, de Vigan C, de Walle H, Feijoo M, Irgens LM, McDonnell B, Merlob P, Ritvanen A, Scarano G, Siffel C, Metneki J, Stoll C, Smithells R, Goujard J (2005) International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? BMJ 330(7491):571
Bowman RM, McLone DG, Grant JA, Tomita T, Ito JA (2001) Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg 34:114–120
Busby A, Abramsky L, Dolk H, Armstrong B, Eurocat Folic Acid Working Group (2005) Preventing neural tube defects in Europe: population based study. BMJ 330(7491):574–575
Campbell J, Gilbert WM, Nicolaides KH, Campbell S (1987) Ultrasound screening for spina bifida: cranial and cerebellar signs in a high-risk population. Obstet Gynecol 70:247–250
Canfield MA, Annegers JF, Brender JD, Cooper SP, Greenberg F (1996) Hispanic origin and neural tube defects in Houston/Harris County. Texas. II. Risk factors. Am J Epidemiol 143:12
Carmichael SL, Shaw GM, Song J, Abrams B (2008) Markers of acculturation and risk of NTDs among Hispanic women in California. Birth Defects Res A Clin Mol Teratol 82(11):755–762
Centers for Disease Control (1992) Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 41(RR-14):1–7
Centers for Disease Control (2004) Spina bifida and anencephaly before and after folic acid mandate—United States, 1995–1996 and 1999–2000. MMWR Morb Mortal Wkly Rep 52:362–365
Centers for Disease Control (2008) Use of supplements containing folic acid among women of childbearing age—United States 2007. MMWR Morb Mortal Wkly Rep 57(1):5–8
Centers for Disease Control (2009) Racial/ethnic differences in the birth prevalence of spina bifida—United States, 1995–2005. MMWR Morb Mortal Wkly Rep 57(53):1409–1413
Chakraborty A, Crimmins D, Hayward R, Thompson D (2008) Toward reducing shunt placement rates in patients with myelomeningocele. J Neurosurg Pediatr 1(5):361–365
Chan A, Robertson EF, Haan EA, Keane RJ, Ranieri E, Carney A (1993) Prevalence of neural tube defects in South Australia, 1966–91, effectiveness and impact on prenatal diagnosis. BMJ 307(6906):703–706
Chen CP (2008) Prenatal diagnosis, fetal surgery, recurrence risk and differential diagnosis of neural tube defects. Taiwan J Obstet Gynecol 47:283–290
Cowchock S, Ainbender E, Prescott G, Crandall B, Lau L, Heller R, Muir WA, Kloza E, Feigelson M, Mennuti M, Cederquist L (1980) The recurrence risk for neural tube defects in the United States: a collaborative study. Am J Med Genet 5:309–314
De Marco P, Calevo MG, Moroni A, Arata L, Merello E, Finnell RH, Zhu H, Andreussi L, Cama A, Capra V (2002) Study of MTHFR and MS polymorphisms as risk factors for NTD in the Italian population. J Hum Genet 47:319–324
Deak KL, Siegel DG, George TM, Gregory S, Ashley-Koch A, Speer MC, NTD Collaborative Group (2008) Further evidence for a maternal genetic effect and a sex-influenced effect contributing to risk for human neural tube defects. Birth Defects Res A Clin Mol Teratol 82(10):662–9
Elwood JM, Elwood JH (1980) Epidemiology of anenecephalus and spina bifida. Oxford University Press, New York, Toronto, pp 85–119
Food and Drug Administration (1996) Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed Regist 61:8781–8797
Frey L, Hauser WA (2003) Epidemiology of neural tube defects. Epilepsia 44(Suppl 3):4
Godwin KA, Sibbald B, Bedard T, Kuzeljevic B, Lowry RB, Arbour L (2008) Changes in frequencies of select congenital anomalies since the onset of folic acid fortification in a Canadian birth defect registry. Can J Public Health 99(4):271–275
Golalipour MJ, Mobasheri E, Vakili MA, Keshtkar AA (2007) Epidemiology of neural tube defects in Northern Iran, 1998–2003. East Mediterr Health J 13(3):560–566
Greene W, Terry R, Demasi R, Herrrington R (1991) Effect of race and gender on neurological level in myelomeningocele. Dev Med Child Neurol 33(2):110–117
Gucciardi E, Pietrusiak MA, Reynolds DL, Rouleau J (2002) Incidence of neural tube defects in Ontario, 1986–1999. Can Med Assoc J 167(3):237–240
Harmon JP, Hiett AK, Palmer CG, Golichowski AM (1980) Prenatal ultrasound detection of isolated neural tube defects: is cytogenetic evaluation warranted? Am J Med Genet 5:595
Harris MJ, Juriloff DM (2007) Mouse mutants with neural tube closure defects and their role in understanding human neural tube defects. Birth Defects Res A Clin Mol Teratol 79:187–210
Hernandez-Dias S, Werler MM, Walker AM, Mitchell AA (2001) Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 153(10):961–968
Hunt GM, Oakeshott P (2003) Long-term outcome in open spina bifida. Br J Gen Pract 53(493):632–636
Hunt GM, Oakeshott P (2003) Outcome in people with open spina bifida at age 35: prospective community based cohort study. BMJ 326(7403):1365–1366
Hunt G, Oakeshott P, Kerry S (1999) Link between the CSF shunt and achievement in adults with spina bifida. J Neurol Neurosurg Psychiatry 67(5):591–595
Johnson MP, Sutton LN, Rintoul N, Crombleholme TM, Flake AW, Howell LJ, Hedrick HL, Wilson RD (2003) Fetal myelomeningocele repair: short-term clinical outcomes. Am J Obstet Gynecol 189:482–487
Jotkowitz AB, Glick S (2006) The Groningen protocol: another perspective. J Med Ethics 32:157
Kadir RA, Sabin C, Whitlow B, Brockbank E, Economides D (1999) Neural tube defects and periconception folic acid in England and Wales: retrospective study. BMJ 319:92–93
Kaufman BA, Terbrock A, Winters N, Ito JA, Klosterman A, Park TS (1994) Disbanding a multidisciplinary clinic: effects on the healthy care of myelomeningocele patients. Pediatr Neurosurg 21:36–44
Kennedy D, Chitayat D, Winsor EJ, Silver M, Toi A (1998) Prenatally diagnosed neural tube defects: ultrasound, chromosome and autopsy or postnatal findings in 212 cases. Am J Med Genet 77:317
Kirke PN, Mills JL, Molloy AM, Brody LC, O’Leary VB, Daly L, Murray S, Conley M, Mayne PD, Smith O, Scott JM (2004) Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case control study. BMJ 328:1535–1536
Laurence K (1974) Effect of early surgery for spina bifida on survival and quality of life. Lancet 1:301–304
Leck I (1966) Changes in the incidence of neural-tube defects. Lancet 2:791–793
Lorber J (1973) Early results of selective treatment of spina bifida cystica. BMJ 4:201
Lorber J (1974) Selective treatment of myelomeningocele: to treat or not to treat? Pediatrics 53:307
Lorber J, Salfield SA (1981) Results of selective treatment of spina bifida cystica. Arch Dis Child 56:822
Manninen BA (2006) A case for justified non-voluntary active euthanasia: exploring the ethics of the Groningen protocol. J Med Ethics 32:643
McLone DG (1983) Results of treatment of children born with a myelomeningocele. Clin Neurosurg 30:407–412
McLone DG (1986) Treatment of myelomeningocele: arguments against selection. Clin Neurosurg 33:359–370
McLone DG (1986) The diagnosis, prognosis and outcome for the handicapped newborn: a neonatal view. Issues Law Med 2:15
McLone DG (1989) Spina bifida today: problems adults face. Semin Neurol 9(3):169–175
McLone DG (2008) Deliberate termination of life of newborns with spina bifida. Childs Nerv Syst 24:33
McLone DG, Dias L, Kaplan WE, Sommers MW (1985) Concepts in the management of spina bifida. In: Humphreys RP (ed) Concepts in Pediatric Neurosurgery, vol 5. Karger, Basel, pp 97–106
Medical Research Council Vitamin Study Research Group (1991) Prevention of neural tube defects: results of the medical research council vitamin study. Lancet 338:131–137
Moretti MD, Bar-Oz B, Fried S, Koren G (2005) Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. Epidemiology 16:216
Mosley BS, Cleves MA, Siega-Riz AM, Shaw GM, Canfield MA, Waller DK, Werler MM, Hobbs CA (2009) Neural tube defects and maternal folate intake among pregnancies conceived after folic acid fortification in the United States. Am J Epidemiol 169(1):9–17
Papp C, Adam Z, Toth-Pal E, Török O, Váradi V, Papp Z (1997) Risk of recurrence of craniospinal anomalies. J Matern Fetal Med 6:57
Persad VL, Van den Hof MC, Dube JM, Zimmer P (2002) Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAJ 167(3):241–245
Sawyer SM, Collins N, Bryan D, Brown D, Hope MA, Bowes G (1998) Young people with spina bifida: transfer from paediatric to adult health care. J Paediatr Child Health 34(5):414–417
Shaer CM, Chescheir N, Schulkin J (2007) Myelomeningocele: a review of the epidemiology, genetics, risk factors for conception, prenatal diagnosis and prognosis for affected individuals. Obstet Gynecol 62(7):471–479
Shurtleff DB (2004) Epidemiology of neural tube defects and folic acid. Cerebrospinal Fluid Res 1:5–9
Sutton LN (2008) Fetal surgery for neural tube defects. Best Pract Res Clin Obstet Gynaecol 22:175
Tulipan N, Bruner JP (1998) Myelomeningocele repair in utero: a report of three cases. Pediatr Neurosurg 28:177
Verhagen AA, Sauer PJ (2005) The Groningen protocol—euthanasia in severely ill newborns. N Engl J Med 352:959
Verhagen AA, Sol JJ, Brouwer OF, Sauer PJ (2005) Deliberate termination of life in newborns in the Netherlands: review of all 22 reported cases between 1997 and 2004. Ned Tijdschr Geneeskd 149:183
Williams LJ, Rasmussen SA, Flores A, Kirby RS, Edmonds LD (2005) Decline in the prevalence of spina bifida and anencephaly by race/ethnicity: 1995–2002. Pediatrics 116:580–586
Woodhouse CRJ (2008) Myelomeningocele: neglected aspects. Pediatr Nephrol 23(8):1223–1231
Zheng XY, Song XM, Chen G, Ji Y, Wu JL, Liu JF, Zhang L, Fan XH (2007) Epidemiology of birth defects in high-prevalence areas of China. Zhonghua Liu Xing Bing Xue Za Zhi 28:5–9
Zlotogora J, Amitai Y, Leventhal A (2006) Surveillance of neural tube defects in Israel: the effect of the recommendation for periconceptional folic acid. Isr Med Assoc J 8(9):601–604
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bowman, R.M., Boshnjaku, V. & McLone, D.G. The changing incidence of myelomeningocele and its impact on pediatric neurosurgery: a review from the Children’s Memorial Hospital. Childs Nerv Syst 25, 801–806 (2009). https://doi.org/10.1007/s00381-009-0865-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00381-009-0865-z